MRM Spain’s Post

That’s a wrap! Thank you Medicines for Europe for another fantastic Value Added Medicines (VAM) Conference. Closing the 5th annual VAM conference our CEO, James Burt perfectly summed up the recurring theme of the day: ‘we’re going to have to work together if we’re want to unleash the power of value added medicines.’ Here’s our key takeaways: - Collaboration is key and early in the process - REALLY involve the patient - Work is needed at a national level to change perception of value #VAMweek #VAMs

Will you be attending the 2023 Safety Pharmacology Society Annual Meeting in Brussels September 18-21? If so, don’t miss your chance to connect with Labcorp about the latest in Pharmacology innovation. We will have a team onsite and would be happy to schedule a meeting to talk about your project needs. Also check out the7 Labcorp posters on display: 1. Validation of an ICH E14/S7B Q&A Best Practice Compliant hERG Assay (#051) 2. Multi-site Validation of in vivo QT ICH E14/S7B Q&A Guidance in Canines and Non-Human Primates (#015) 3. Assessment of Moxifloxacin-induced QTc Prolongation in Canine and Nonhuman Primate Using a Linear Mixed Effect Modeling Approach (#017) 4. Evaluation of the Head Twitch Response in Male C5BL/6 Mice as a Measure of 5-HT2a Receptor Activation (#029) 5. An Investigation into the Relationship between Acetazolamide Systemic Exposure, Blood Gas Changes and Ventilatory Parameters in the Sprague Dawley Rat (#124) 6. Evaluating the Cardiovascular Effects of Lipid Nanoparticle-Encapsulating mRNA Therapeutics in Cynomolgus Monkeys Using Telemetry and Star-Oddi Logger Devices (#133) 7. Cardiovascular Assessment of Lipid Nanoparticle-Encapsulating mRNA Therapeutics in Rats using Telemetry and Star-Oddi Logger Devices (#135) And we are privileged to be a part of 5 industry working group collaborative posters: 1. Heart Rate Corrected JTp and Tpe as Proarrhythmia Biomarkers in Safety Pharmacology Non-Human Primate Studies: Outcome from a HESI Consortium Prospective Study (#025) 2. Towards Best Practices: A Cross-Company Survey of Nonclinical C-QT Analysis in Drug Development (#023) 3. Best Practice Considerations for Nonclinical In Vivo Cardiovascular Telemetry Studies with Alternative Study Designs in Non-Rodent Species (#013) 4. An Evaluation of Drug-Induced Blood Pressure Changes in a Standard Canine CV Safety Pharmacology Study: a HESI-sponsored Consortium (#026) 5. Recommendations on the Measurement of Electrocardiogram and Hemodynamic Parameters in Restrained Non-rodent Species in Regulatory Safety Assessment Studies (#007)

Our team, Dr. Raafat Fares, PhD - ERBC (European Research Biology Center) Scientific Director and Dr. Pascal Champeroux, PhD - ERBC Chief Scientific Officer, are currently at the Safety Pharmacology Society 2023 Annual Meeting. During these days, they will be chairing and speaking in several insightful sessions. We encourage you to explore the event program details through this link to learn more.   #Lifescience #CRO #nonclinical #drugdevelopment #animalwelfare #proofofconcept #toxicology #safetypharmacology 

Really looking forward to a FANTASTIC Safety Pharmacology Society meeting in Brussels next week!   I am excited to be part of the Wednesday Track A session: Experimental Insights Toward Best Practices of In Vivo QTc Assay with Translational Value, and will explore best practices for in vivo methodologies in my talk titled: Step-by-Step Tutorial on Conduct of an In Vivo Telemetry Study Compliant with the New S7B Q&A Guidance.   Labcorp colleagues will also have 7 posters on display. Please stop by and chat with our scientists about all their hard work. They would love to speak with you!   -Validation of an ICH E14/S7B Q&A Best Practice Compliant hERG Assay (#051) -Multi-site Validation of in vivo QT ICH E14/S7B Q&A Guidance in Canines and Non-Human Primates (#015) -Assessment of Moxifloxacin-induced QTc Prolongation in Canine and Nonhuman Primate Using a Linear Mixed Effect Modeling Approach (#017) -Evaluation of the Head Twitch Response in Male C5BL/6 Mice as a Measure of 5-HT2a Receptor Activation (#029) -An Investigation into the Relationship between Acetazolamide Systemic Exposure, Blood Gas Changes and Ventilatory Parameters in the Sprague Dawley Rat (#124) -Evaluating the Cardiovascular Effects of Lipid Nanoparticle-Encapsulating mRNA Therapeutics in Cynomolgus Monkeys Using Telemetry and Star-Oddi Logger Devices (#133) -Cardiovascular Assessment of Lipid Nanoparticle-Encapsulating mRNA Therapeutics in Rats using Telemetry and Star-Oddi Logger Devices (#135)   Labcorp is also privileged to be a part of 5 industry working group collaborative posters:   -Heart Rate Corrected JTp and Tpe as Proarrhythmia Biomarkers in Safety Pharmacology Non-Human Primate Studies: Outcome from a HESI Consortium Prospective Study (#025) -Towards Best Practices: A Cross-Company Survey of Nonclinical C-QT Analysis in Drug Development (#023) -Best Practice Considerations for Nonclinical In Vivo Cardiovascular -Telemetry Studies with Alternative Study Designs in Non-Rodent Species (#013) -An Evaluation of Drug-Induced Blood Pressure Changes in a Standard Canine CV Safety Pharmacology Study: a HESI-sponsored Consortium (#026) -Recommendations on the Measurement of Electrocardiogram and Hemodynamic Parameters in Restrained Non-rodent Species in Regulatory Safety Assessment Studies (#007) https://lnkd.in/gmKgN5PD

The #WODC conference is coming up next week. Join our CCO Dennis Akkaya as he moderates a panel discussion on Oct 31 at 16:10 with recognized experts Ramona Reichenbach (Novartis), Pedro Franco (Merck Serono), and François Houÿez (EURORDIS) as they delve into ‘Compassionate Use in the EU: Challenges and the Path to Harmonization’, discussing the current landscape and a path forward.      Under the moderation of Dennis, the dialogue will provide an insightful overview on:    📚 A Comprehensive Overview: Journey through the historical to current regulations of compassionate use in the EU.  🏔 Challenges Unveiled: Active discussion about the hurdles and bottlenecks in the EU Compassionate use process.  🎯 Actionable Insights: Learn about real-world pathways and solutions to harmonize compassionate use practices.    Also attending are our mighty team of Jasmin Schelhaas Eline Heidenrijk and Angela Sarmiento Betancourt. Are you attending? Come visit us at our booth 8️⃣ 6️⃣ and speak with our team about our expertise in #CompassionateUse, #ExpandedAccess programs, and #RWD collection, as well as our #CTRecruitment offering and learn more about latest developments within pre-approval access for BioPharma.    Follow myTomorrows and World Orphan Drug Congress Europe for more. #raredisease #orphandrug --> see the agenda -->  https://lnkd.in/dkxcGrX 

Are you curious about how trends in real word evidence (RWE) are shaping decision-making in healthcare? Join us at #ISPORAnnual for an insightful research poster tour that includes insights for leveraging RWE in non-oncology submissions in the UK, France, and Germany. Taking place at PT43 on May 7 from 3:30-4:15, we'll provide a brief overview of our findings and engage in a lively discussion with delegates and the knowledgeable tour guide. Discover key insights from our analysis of health technology assessment (HTA) submissions to NICE, HAS, and the G-BA, including: - The prevalence of RWE in non-oncology submissions - Trends in the use and acceptability of RWE across different markets - Various ways RWE is utilized to support clinical effectiveness, tolerance, and cost-effectiveness. Authors: Ally Robert and Vasileios Pardalidis, Avalere Health. Meet us on the poster tour to gain valuable knowledge and contribute to the discussion. Schedule a meeting with us at Booth 413: https://lnkd.in/eAxvzZha #HEOR #MarketAccess #RWE #HTA #WeAreAvalereHealth

Reflecting on a great few days at #wodc in Barcelona our team are sharing their key takeaways. Rachel Cummings is Principal Consultant for Market Access and Real World Evidence at #teamdecisive and participated in a panel session with other experts exploring the role of Early Access programmes in demonstrating the value of orphan medicines. Early Access and RWE are just two of the many topics we work with our clients to devise, plan and implement. Do get in touch if you'd like to know more. #marketaccess #hta #heor #earlyaccess #orphandrugs

On this World Sickle Cell Anemia Day, let's come together to raise awareness and show our support for those affected by this challenging condition. Sickle cell anemia is a genetic disorder that affects millions worldwide, causing severe pain, complications, and a significant impact on quality of life. Today, we stand in solidarity with patients and their families, advocating for better treatment options, more research funding, and broader education on this disease. Together, we can make a difference and move towards a future where sickle cell anemia is better understood, managed, and ultimately cured. #sicklecellawareness #worldsicklecellday

Sarcoidosis Awareness Month! 🗓 As we delve deeper into the Month of Sarcoidosis Awareness, last week marked a pivotal moment for our ongoing efforts in combating #PulmonarySarcoidosis. ODC orchestrated a dynamic Investigator Meeting in collaboration with aTyr Pharma, focusing on our groundbreaking trial currently underway in Brazil, aimed at recruiting patients for this critical cause. The trial sites' collective expertise and commitment generated insightful discussions delving into the trial itself and the intricacies of Pulmonary Sarcoidosis. Together, we are not only advancing science but also reshaping lives! #PulmonarySarcoidosisAwareness #ClinicalResearch #MedicalInnovation

🌐 Exciting discussions at the III International Pharmaceutical Forum "Global Pharm"! 🏥 One of the engaging sessions that caught our attention was the panel discussion on "Value-Oriented Approach – Managing Healthcare Systems Based on Results". Vyacheslav Dudnik, the Deputy Minister of Healthcare of Kazakhstan, shared valuable insights into why Value-Based Healthcare (VBH) is essential. He highlighted that the current healthcare payment system primarily considers the volume of medical services, and there's a pressing need to shift towards a system that focuses on patient outcomes. What is Value-Based Healthcare (VBH)? Value-Based Healthcare (VBH) is a patient-centered approach that prioritizes the quality and effectiveness of healthcare services over sheer quantity. It ensures that healthcare providers are incentivized to deliver high-quality care that leads to improved patient health and satisfaction. VBH aligns healthcare incentives with the best interests of patients. Why is VBH Important? 1. Enhanced Patient Outcomes: VBH encourages healthcare providers to concentrate on what matters most – the well-being of the patient. It drives improvements in care quality, resulting in better health outcomes and higher patient satisfaction. 2. Efficiency: By emphasizing value over volume, VBH reduces unnecessary procedures and treatments, resulting in cost savings for healthcare systems and patients. 3. Transparency: VBH relies on transparent data and outcomes measurement, fostering accountability and driving continuous improvement in healthcare delivery. 4. Patient-Centered Care: VBH empowers patients to make informed choices about their healthcare and actively participate in their treatment decisions.   The panel discussion also featured insightful presentations by prominent speakers: - Claudia Ricardo, Market Access & External Affairs Director, Roche Portugal - Lauma Valtere, Managing Director Kazakhstan, CCL Pharmaceutical (CIS countries, except Russia) at Bayer - Toylan Senel, General Manager Roche Kazakhstan, Head Roche Central Asia - Altynshash Dzhaksybayeva, Chief Pediatric Neurologist of the Ministry of Health of the Republic of Kazakhstan, MD, Head of the Department of Neurology, Medical University Astana - Alexey Scherbinsky, Head of the Main Department of Medical Care Organization of the Ministry of Health of the Republic of Belarus 🚀 These discussions are a significant step towards a more patient-centered and results-driven healthcare system. Together, we can make a positive impact on healthcare delivery in the region. #GlobalPharm #Healthcare #VBH #ResultsDrivenHealthcare 🏆